Literature DB >> 1825455

Human platelet aggregation and shape change are coupled to separate thromboxane A2-prostaglandin H2 receptors.

G W Dorn1, A DeJesus.   

Abstract

The relationships of human platelet thromboxane A2-prostaglandin H2 (TxA2/PGH2) receptor occupation as assessed by equilibrium binding of the TxA2/PGH2 agonist [125I]BOP to the functional responses of I-BOP-induced platelet shape change and aggregation were determined before and after specific, irreversible inactivation of platelet TxA2/PGH2 receptors with the photolyzable TxA2/PGH2 antagonist I-PTA-PON3. I-BOP stimulated platelet shape change and aggregation with concentrations producing a half-maximal response of 173 +/- 39 pM (n = 4) and 1.8 +/- 0.4 nM (n = 6), respectively (means +/- SE). Covalent inactivation of TxA2/PGH2 receptors with I-PTA-PON3 caused rightward shifts of I-BOP shape change and aggregation dose-response curves and resulted in pharmacological dissociation constants (Kd) of 134 pM and 1.95 nM, respectively. Isotherms of [125I] BOP binding to intact platelets (n = 6) were shallow with Hill coefficients of -0.68 +/- 0.03 and were best described by a two-site model with 222 +/- 58 sites/platelet of high affinity (Kd = 270 +/- 60 pM) and 818 +/- 90 sites/platelet of lower affinity (Kd = 3.9 +/- 1.2 nM). The relationship of I-BOP occupancy of high-affinity receptors to shape-change responses was linear (r = 0.97, P less than 0.001), but the occupancy-response relationship for the lower affinity receptor and platelet aggregation was hyperbolic with half-maximal aggregation occurring after occupation of 25% of the receptors. After covalent inactivation of a variable proportion of the receptors with I-PTA-PON3, the occupancy-response relationship for platelet aggregation resulted in a similar hyperbola indicating an excess of low-affinity receptors coupled to aggregation (spare receptors).(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1825455     DOI: 10.1152/ajpheart.1991.260.2.H327

Source DB:  PubMed          Journal:  Am J Physiol        ISSN: 0002-9513


  7 in total

1.  New concept of spare receptors and effectors.

Authors:  Y Marunaka; N Niisato; H Miyazaki
Journal:  J Membr Biol       Date:  2005-01       Impact factor: 1.843

2.  Thromboxane A2-mediated shape change: independent of Gq-phospholipase C--Ca2+ pathway in rabbit platelets.

Authors:  S Ohkubo; N Nakahata; Y Ohizumi
Journal:  Br J Pharmacol       Date:  1996-03       Impact factor: 8.739

3.  Intrinsic activity of the non-prostanoid thromboxane A2 receptor antagonist, daltroban (BM 13,505), in human platelets in vitro and in the rat vasculature in vivo.

Authors:  F Bertolino; J P Valentin; M Maffre; F Grelac; A M Bessac; J Maclouf; A Delhon; S Lévy-Toledano; J F Patoiseau; F C Colpaert
Journal:  Br J Pharmacol       Date:  1995-05       Impact factor: 8.739

4.  Thromboxane-insensitive dog platelets have impaired activation of phospholipase C due to receptor-linked G protein dysfunction.

Authors:  G J Johnson; L A Leis; P C Dunlop
Journal:  J Clin Invest       Date:  1993-11       Impact factor: 14.808

Review 5.  Pathophysiology of isoprostanes in the cardiovascular system: implications of isoprostane-mediated thromboxane A2 receptor activation.

Authors:  Jochen Bauer; Anne Ripperger; Stefan Frantz; Süleyman Ergün; Edzard Schwedhelm; Ralf A Benndorf
Journal:  Br J Pharmacol       Date:  2014-07       Impact factor: 8.739

6.  Two thromboxane A2 receptor isoforms in human platelets. Opposite coupling to adenylyl cyclase with different sensitivity to Arg60 to Leu mutation.

Authors:  T Hirata; F Ushikubi; A Kakizuka; M Okuma; S Narumiya
Journal:  J Clin Invest       Date:  1996-02-15       Impact factor: 14.808

7.  Aging-shifted prostaglandin profile in endothelium as a factor in cardiovascular disorders.

Authors:  Hao Qian; Na Luo; Yuling Chi
Journal:  J Aging Res       Date:  2012-02-13
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.